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ABSTRACT 
Objective:  
Juvenile dermatomyositis (JDM) is a rare and severe autoimmune condition characterized by 
rash and proximal muscle weakness. While some patients respond to standard treatment, 
others do not. We investigated whether histopathology and myositis-specific autoantibodies 
(MSA) have prognostic significance. 
Methods: 
Muscle biopsy samples (n=101) from the UK JDM Cohort and Biomarker Study were 
stained, analyzed and scored. Autoantibodies were measured (n=90) and longitudinal clinical 
data were collected (median follow-up 4.9 years). Long-term treatment status was modelled 
using generalized estimating equations.  
Results: 
Muscle biopsy scores differed according to MSA. When effects of MSA were accounted for, 
increased severity of muscle pathology predicted increased risk of remaining on treatment 
over time: 1.48-fold higher odds (1.12-1.96, p=0.0058) for the global pathology score 
(hVAS) and 1.10-fold higher odds (1.01-1.21, p=0.038) for the total biopsy score for the 
standardized score tool. A protective effect was identified in patients with anti-Mi2 
autoantibodies, who had 7.06-fold lower odds (1.41-35.36, p=0.018) of remaining on 
treatment, despite displaying more severe muscle pathology at biopsy. For patients with anti-
NXP-2, anti-TIF1γ autoantibodies or no-detectable autoantibody, increased severity of 
muscle pathology alone could predict the risk of remaining on treatment, without adjustment 
for MSA: 1.61-fold higher odds (1.16-2.22, p=0.0040) for hVAS and 1.13-fold higher odds 
(1.03-1.24, p=0.013) for total biopsy score.  
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Conclusion: 
Muscle pathology, in combination with MSA, predicts the risk of remaining on treatment in 
JDM and may be useful for discussing probable treatment length with parents and patients. 
Understanding these associations may identify patients at greater risk of severe disease.  
 
 
  
Page 5 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
5 
 
Accurate prediction of outcomes is a common problem in rare diseases. For many rare 
diseases, including juvenile myositis, patients and clinicians have an unmet need to predict 
poor outcomes. A further challenge in the study of rare autoimmune diseases is that disease 
mechanisms may be unknown, which renders biomarker research difficult. Juvenile 
dermatomyositis (JDM) is an example of a rare disease where the disease pathogenesis is 
only partially understood. A chronic autoimmune condition of childhood, JDM is typically 
characterized by proximal muscle weakness, elevated levels of muscle enzymes in serum, and 
rashes such as heliotrope rash and Gottron’s papules (1). Other clinical features which 
contribute major morbidity include calcinosis, ulceration, treatment-resistant rash and 
involvement of the gut, lungs and brain. While some patients achieve remission following 
standard disease management, others fail to respond. In a recent long-term outcome study of 
59 adults who had had JDM, with median follow-up of 16 years, 51% still had active disease 
(2). At present, early biomarkers of disease that are associated with long-term outcomes have 
not been identified. 
To facilitate research into biological mechanisms, biomarkers and disease outcomes, 
the UK JDM Cohort and Biomarker Study (JDCBS; n=506 at time of writing) was 
established to collect serial clinical data and biospecimens (3). Such studies open the 
potential for the classification of rare diseases into sub-types defined by biomarkers and 
associated with predictable outcomes, and investigation of disease mechanisms that drive 
these sub-types. Biomarker research may eventually enable development of therapies directed 
against more relevant targets for particular subtypes, ultimately leading to better clinical 
outcomes. Myositis-specific autoantibodies (MSA) have been identified in both adult-onset 
dermatomyositis (DM) and JDM, and include anti-Mi2, anti-melanoma differentiation-
associated gene 5 (MDA5), anti-transcriptional intermediary factor 1-γ (TIF1γ; p155/140) 
and anti-nuclear matrix protein (NXP-2; p140, also identified as the anti-MJ autoantibody). 
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Associations have been demonstrated between MSA and certain clinical features, suggesting 
that these autoantibodies may be useful biomarkers (4–11). However, little is known about 
the biological mechanisms underlying different MSA sub-types or how they relate to long-
term prognosis.  
We have previously developed and validated a standardized score tool to quantify 
abnormalities in JDM muscle biopsies (12,13). Use of immunohistochemistry to predict 
prognosis and inform treatment is well-established in more prevalent diseases such as 
malignancy. Here, we applied the standardized JDM score tool to a large cohort of biopsy 
samples (n=101) and tested the hypothesis that early JDM muscle pathology contains 
information predictive of long-term treatment status.  
 
PATIENTS AND METHODS 
Patients, biopsy material and clinical data 
Pediatric patients with definite or probable JDM (14) were recruited to the UK JDCBS 
(n=506). Written informed parental consent and age appropriate assent were obtained from 
participants prior to inclusion in the study. This research was approved by the Northern & 
Yorkshire Medical Research and Ethics Committee (MREC), UK. All muscle biopsy samples 
available from the JDCBS (3) were analyzed where tissue was of sufficient quantity and 
quality (n=101). All tissue samples were obtained by open quadriceps biopsy under general 
anesthetic. Most of these patients (94.1%) were treated at Great Ormond Street Hospital for 
Children (GOSH), a major referral center, where the policy is to perform routine biopsy at 
time of diagnosis in patients with JDM. Consequently, a wide range of severities from mild to 
moderate are represented in the biopsied patients (Figure S1, A and B). Although the 
distribution of disease severity scores at diagnosis was more skewed towards increased 
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severity in those with a biopsy than cased who did not have a biopsy (Table S1, Figure S1,C 
and D), the unbiopsied patients were also more likely to have missing data at diagnosis and 
therefore these data are difficult to interpret. 
Clinical data collected at diagnosis and biopsy included the physician’s global 
assessment (PGA; range 0-10; low scores indicate minimal disease), Manual Muscle Testing 
and a Subset of Eight Muscles (MMT8; range 0-80; high scores indicate no muscle 
weakness) (15), Childhood Myositis Assessment Scale (CMAS; range 0-52; high scores 
indicate no weakness) (16), serum creatine kinase levels (units/L). Treatments received by 
patients were also recorded at each clinical visit. At diagnosis, all patients received 
methotrexate and the majority received concomitant steroids in agreement with international 
protocols (17). Where disease was unresponsive to treatment with methotrexate, other 
disease-modifying anti-rheumatic drugs (DMARDs) were used, including azathioprine, 
hydroxychloroquine, intravenous immunoglobulin and cyclophosphamide. For patients who 
still had refractory disease, anti-tumor necrosis factor biological agents (infliximab or 
adalimumab) were used. None of the analyzed patients were treated with cyclosporine A.  
Histology and biopsy scoring 
Histological staining, analysis and scoring of biopsy samples were conducted as described 
previously, using the validated JDM biopsy score tool to calculate a total biopsy score 
(12,13). The histopathologist’s visual analogue scale score (hVAS) provides a global 
assessment of the severity of muscle pathology. Values for the total biopsy score (which 
includes assessment in 4 domains) and hVAS range from 0-27 and 0-10, respectively, with 
higher scores indicating more severe pathology. All histology and scoring were performed by 
a single observer (S.A.Y.), blind to the autoantibody status of each JDM case, trained by two 
highly qualified consultant neuropathologists who are experienced specialists in the field 
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(T.S.J. and J.L.H.), and who were involved in the development and validation of the JDM 
biopsy score tool  (12,13). For the initial 9 biopsies, scores were firstly cross-compared with 
those of the two trainers and secondly with those generated by an international panel during 
the validation of the score tool (13), to ensure reliability. The intraclass correlation coefficient 
for the hVAS of the observer and those of the international panel for those 9 cases was 0.80 
(0.62-0.95), indicating high levels of agreement.  
Autoantibody screening 
Serum or plasma were screened for autoantibodies as described previously using 
immunoprecipitation (5,9–11). Specificity for anti-NXP-2 or anti-MDA5 in patients with a 
140 kDa band was determined by ELISA as described previously (5,11). Since recent 
literature has identified important associations between clinical features and MSA (4–11), 
and relatively fewer MAA cases were present in the biopsy cohort with low numbers in 
individual groups, we elected to focus on patient groups with sufficient frequency of MSAs 
to analyze i.e. anti-TIF1γ, anti-NXP-2, anti-MDA5 and anti-Mi2. Patients with MAA or 
unidentified bands were excluded during the statistical analyses of associations with muscle 
pathology and associations with muscle pathology and long-term outcomes. Patients with no-
detectable autoantibody were included.  
Statistics: data analysis and longitudinal modelling 
Correlation between total biopsy scores and hVAS was analyzed using Spearman’s rank 
correlation coefficient in R version 3.2.1 (18). A factorial analysis of variance (ANOVA) was 
conducted using the non-parametric Kruskal-Wallis test in R to identify significant main 
effects of MSA sub-groups on biopsy scores. Post-hoc comparisons to identify pairs of MSA 
sub-groups that significantly differed from each other were performed using R package 
dunn.test, with p-values adjusted using the Bonferroni method (19). For each medication, the 
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distribution of whether that drug was ever received by patients across each MSA sub-group 
was analyzed using Fisher’s exact test in R, with p-values adjusted using the Bonferroni 
method.  
A longitudinal modelling approach, which could include all available time-points for 
each patient, was adopted for the analysis of the treatment status outcome in order to make 
maximal use of the available serial clinical data. A longitudinal approach was preferred over 
a cross-sectional approach, which is limited to arbitrarily-selected time-points of interest and 
ignores any other time-points. Recurrent event analysis was preferred over time-to-event 
analysis, which is limited to time-points up to the first time patients come off treatment and 
ignores subsequent time-points when patients may come on treatment again. Longitudinal 
modelling of long-term treatment status was performed using generalized estimating 
equations (GEE), a longitudinal method for analyzing recurrent events which provides more 
conservative estimates for modelling binary outcomes than mixed-effects models (20–22). 
GEE models were fitted using R package geepack and an autoregressive correlation structure 
(23). Date of diagnosis was the zero time-point. Time from diagnosis was used as the time 
variable, which ensured that the effects of treatment duration were adjusted for. The no-
detectable autoantibody group (n=20) was the reference category for the MSA variable to 
enable more precise estimates, since this group had the most patients. Although the biopsied 
patients are predominantly an inception cohort, a mixture of incident and prevalent patients 
were recruited when the JDCBS was started. For this reason, time from disease onset to 
diagnosis and time from diagnosis to biopsy were considered as potential confounders in 
longitudinal modelling. Since time from disease onset to diagnosis and time from diagnosis to 
biopsy were both found to have significant effects, these confounders were retained as 
covariates in subsequent analyses. Thus, all parameter estimates are adjusted for the effects of 
time from disease onset to diagnosis and time from diagnosis to biopsy. Additional 
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potentially confounding variables were evaluated, and included sex, whether steroids had 
been received before biopsy, and treatment ever with cyclophosphamide, but none of these 
had a significant effect in the model, so were not retained. Estimates of odds ratios are 
presented as odds of being on treatment, with 95% confidence intervals. Since odds ratios 
below 1 can be difficult to interpret, odds ratios below one are also presented as the odds of 
being off treatment.  
Parameter estimates from the GEE models were used to formulate an equation to 
calculate the odds and hence predicted probability of being off treatment. To enable predicted 
probability to be plotted as a function of hVAS or total biopsy score, a fixed time-point of 5 
years post-diagnosis was used. Median values for the time from onset to diagnosis and time 
from diagnosis to biopsy confounding variables were used. Plots were generated using a 
customized R function and the base plotting system.  
Bivariate, univariate and null GEE models were compared using ANOVA for 
comparison of nested models, and R package MuMIn for calculation of the quasi-Akaike 
information criterion (QIC) and the proportion of weighting for the preferred model using the 
function model.sel() (24). ANOVA uses a χ
2
 distribution to test the likelihood ratios of the 
models being compared. QIC is a measure of the relative quality of a GEE model, with lower 
values indicating an improved fit. For the model comparison analyses, the QIC values, 
proportion of weighting calculated by model.sel(), χ
2
 statistics and p-values are reported.  
For longitudinal modelling, p-values <0.05 were considered statistically significant. 
Summary statistics are presented as median and interquartile range for numeric variables, and 
as counts and percentages for categorical variables. Ninety-five per cent confidence intervals 
are presented for all estimated parameters. Figures depicting correlation and distribution of 
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biopsy scores and forest plot depictions of odds ratios were generated using GraphPad Prism 
5.01 (GraphPad Software, San Diego, USA).  
 
RESULTS 
Demographic, clinical and serological features of the biopsy cohort 
The 101 patients in this analysis were predominantly female, white and represented a range 
of disease severities (Table 1). The MSA analyzed in this study were detected in 58.9% of 
screened patients, including: anti-TIF1γ (20.0%), anti-NXP-2 (16.7%), anti-MDA5 (12.2%), 
and anti-Mi2 (5.6%). Myositis-associated autoantibodies (MAA) were detected in 10.0% of 
patients, unidentified bands were detected in 8.9% of patients and no autoantibodies were 
detected in 22.2% of patients.  
Pathology scores are differentially distributed according to autoantibody status 
The biopsy hVAS and total biopsy scores were highly correlated (R=0.88, p<0.0001; Figure 
1A), indicating internal consistency of the tool. Biopsy hVAS and total biopsy scores 
included low and high scores and were not skewed towards either the more severe or milder 
ranges (Figure S1). Interestingly, there were clear differences in the distribution of both the 
hVAS and total biopsy scores between the major MSA sub-groups and the no-detectable 
autoantibody cases (p=0.0005, Figure 1B; and p=0.0004, Figure 1C). Anti-Mi2 and anti-
MDA5 cases typically displayed severe and mild pathology, respectively. Anti-MDA5 cases 
had significantly lower hVAS and total biopsy scores than all other groups. Variable levels of 
severity were observed for the anti-NXP-2, anti-TIF1γ and no-detectable autoantibody 
groups. 
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Muscle pathology is associated with long-term treatment status and this effect is 
influenced by autoantibody status 
We next investigated whether MSA and muscle pathology are associated with the long-term 
outcome of continued medication over time. The treatment status outcome was selected as an 
outcome of clinical importance to both patients and clinicians. Medications included the 
immunosuppressive, chemotherapeutic and biological agents detailed in the methods, and 
were not differently distributed across MSA sub-groups (Table S2). In the GEE models fitted 
with MSA and either hVAS or total biopsy score as covariates, both hVAS and total biopsy 
score had a significant effect on long-term treatment status (Figure 2). In the model fitted 
with hVAS and MSA as covariates, a unit increase in hVAS was associated with 1.48-fold 
higher odds (1.12-1.96; p=0.0058) of being on treatment over time (Figure 2A).  
 The overall pattern of the GEE model fitted with both MSA and total biopsy score as 
covariates was similar to the model fitted with both MSA and hVAS, although the magnitude 
of the effect sizes and statistical significance were smaller (Figure 2B). A unit increase in 
total biopsy score was associated with 1.10–fold higher odds (1.01-1.21; p=0.038) of being 
on treatment over time.  
Anti-Mi2 cases have higher odds of coming off treatment  
Interestingly, the anti-Mi2 antibody appeared to have a protective effect, with these patients 
having 7.06-fold lower odds (1.41-35.36, p=0.018) of remaining on treatment over time. This 
finding was counter-intuitive, since these cases had more severe muscle pathology (Figure 1B 
and Figure 1C). However, this estimate has wide 95% confidence intervals and warrants 
cautious interpretation. Anti-Mi2 had a borderline insignificant protective effect in the model 
fitted with total biopsy score as a covariate. In contrast to the anti-Mi2 cases, patients with the 
Page 13 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
13 
 
anti-MDA5 antibody displayed a non-significant trend towards higher odds of remaining on 
treatment over time, despite having less severe muscle pathology at biopsy. 
Muscle pathology or autoantibody status alone do not predict prognosis 
To examine the question of whether biopsy hVAS, total biopsy score or MSA alone could 
predict long-term treatment status, univariate GEE models were fitted (Table 2). In these 
univariate models, none of hVAS, total biopsy score or MSA sub-groups had significant 
effects alone, even though these measures had significant effects in the bivariate models that 
included both muscle pathology and MSA. When the univariate models were compared to the 
bivariate models, the bivariate models were a better fit for the data (Table 3). Therefore, 
when all MSA cases were assessed, muscle pathology alone or MSA alone were not 
predictive of prognosis.  
Muscle pathology is a better prognostic indicator than physician’s global assessment at 
diagnosis  
We also tested whether substituting muscle pathology score with PGA at diagnosis resulted 
in better prediction of treatment status. PGA at diagnosis did not have a statistically 
significant effect (Table 2), and this model was not a better fit than models with MSA and 
either hVAS or total biopsy score as covariates (Table 3).  
For anti-NXP-2, anti-TIF1γ and autoantibody-negative cases, muscle pathology alone 
predicts long-term treatment status 
Given the divergent effects of anti-Mi2 and anti-MDA5 in the GEE models fitted with MSA 
and muscle pathology scores (Figure 2), we reasoned that taking out these diametrically-
opposed groups and any potentially overshadowing effects of those groups would enable 
further analysis of the anti-NXP-2, anti-TIF1γ and autoantibody-negative cases, which are the 
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most prevalent MSA groups. In this analysis, muscle pathology alone was associated with 
long-term treatment status (Figure 3). A unit increase in hVAS was associated with 1.61-fold 
higher odds (1.16-2.22, p=0.0040) of remaining on treatment over time (Figure 3A), while a 
unit increase in total biopsy score was associated with 1.13-fold higher odds (1.03-1.24, 
p=0.013) of remaining on treatment over time (Figure 3B). Inclusion of MSA as a covariate 
did not improve the fit (Table 3). Furthermore, the estimates for these univariate models 
where just the anti-NXP-2, anti-TIF1γ and autoantibody-negative cases were considered are 
similar to those when all MSA sub-groups were considered and the effect of MSA was 
accounted for (Figure 2). This indicates the equivalence of these sets of models and also the 
need to account for the effect of MSA when all MSA cases are considered.  
Finally, to facilitate interpretation of these models, the predicted probability of being 
off treatment was plotted as a function of muscle pathology at a given time-point of 5 years 
post-diagnosis (Figure 3C and Figure 3D). These representations show the predicted 
probability of being off treatment at 5 years decreases as muscle pathology becomes more 
severe. For example, a patient with anti-NXP-2, anti-TIF1γ or no-detectable autoantibody and 
an hVAS score below 2 would have an over 50% probability of being off treatment 5 years 
after diagnosis. However, if the hVAS score is over 8, the estimated probability of being off 
treatment at 5 years after diagnosis is below just 6%.  
 
DISCUSSION 
Our study demonstrates that MSA are linked to muscle pathology in juvenile myositis. 
Furthermore, we show MSA influences the relationship between muscle pathology and long-
term treatment status in JDM. Such knowledge may assist with identifying patients more 
likely to respond to treatment, versus those who are less likely to respond and may need more 
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aggressive treatment early in disease. This is also the first study to identify long-term clinical 
patterns in JDM patients with anti-Mi2 autoantibodies. It is intriguing that anti-Mi2 was 
associated with good prognosis despite being linked to severe muscle pathology, and also that 
there appeared to be an opposite trend for anti-MDA5. It may be that existing 
immunosuppressive therapies are more effective against the predominant muscle involvement 
that characterizes anti-Mi2 patients, but not for the anti-MDA5 patients, who have more 
extra-muscular features. For patients with anti-NXP-2, anti-TIF1γ or no-detectable 
autoantibodies, the severity of muscle pathology alone predicted the probability of remaining 
on treatment over time. Our results suggest treatment response is MSA-specific, implying 
distinct pathophysiology in MSA sub-groups. Therefore, there is a need for further research 
and consequently therapies targeting specific pathways identified as aberrant in these sub-
types.  
 In addition to their usefulness for confirming diagnosis, our analysis shows that 
biopsies contain important information which, in combination with MSA, has prognostic 
significance. If our findings are replicated using larger patient numbers, performance of 
muscle biopsy routinely during diagnostic work-up may be justified in JDM. A recent study 
in adult DM also suggested that histopathology varies with MSA, but that study did not 
include analysis of MSA or histology against outcome (25). In other fields, such as breast 
cancer and glomerulonephritis, histology is used to classify heterogeneous disease into sub-
types to inform optimal treatment regimens (26,27). Such stratified medicine approaches may 
have application to rare heterogeneous diseases like JDM.  
 In our analysis, the effect size and statistical significance of the hVAS were greater 
than those of the total biopsy score. Although this global pathology assessment correlates 
well with the standardized biopsy score, these 2 parts of the biopsy tool may measure 
pathology in different ways. The hVAS has more flexibility and sensitivity to give weight to 
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features that affect the severity of pathology, and are unaddressed by the specific items within 
the score tool. Even though the hVAS is based on the individual histopathologist’s judgment, 
the hVAS was found to have high inter- and intra-observer reliability during the development 
and validation of the score tool (12,13).  
 Although this study used a large number of JDM biopsy samples (n=101), the 
relatively low numbers of patients within MSA sub-groups limits the precision of the GEE 
estimates for the MSA sub-groups, which have wide confidence intervals. For example, the 
protective effect identified for anti-Mi2 is based on just 5 patients and the estimate has a wide 
95% confidence interval, although the statistical significance of the association nonetheless 
holds. Low numbers also restricted our ability to fit more complex models, such as allowing 
for interactions between MSA sub-groups and pathology score. Due to the low numbers of 
individual MSA sub-groups, we consider the most reasonable interpretation of our analysis to 
be that muscle pathology predicts long-term treatment status and that this effect is influenced 
by MSA. This finding is based on all MSA patients analyzed (n=69). Ideally, these findings 
should next be validated in an independent patient cohort, but at present there are few centers 
that routinely obtain muscle biopsies from JDM patients and to our knowledge, this study 
represents the largest JDM cohort in which biopsy data are linked to autoantibody status and 
up to 15 years of clinical data. As other JDM cohorts with biopsy data are built on, it will be 
important to use these to validate these findings. Low numbers is a challenge for any rare 
disease study, and the knowledge gained from this study highlights the importance of long-
term biospecimen cohort studies in rare diseases. We also recognize that our findings cannot 
be extrapolated beyond the MSA groups analyzed, and further studies should examine the 
associations between MAA and pathology using greater numbers of patients.  
A second limitation is that the treatment status outcome modelled in this study is 
linked only indirectly to disease pathology. Treatment status was selected as an outcome that 
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is meaningful for patients and clinicians, and which could be addressed using our dataset. It 
also fluctuates less than other outcomes measures we considered, such as “clinically 
insignificant disease” (28), and thus is more amenable to fitting complex longitudinal models. 
Defining appropriate outcome measures is still an active area of JDM research, and new 
measures will facilitate research into biomarkers and outcomes. Since treating clinicians were 
not all blinded to biopsy and MSA results, it is possible those findings could have influenced 
treatment practice, although the relationship between histology, MSA and outcomes is still at 
the research stage, and was not known to clinicians at the time treatment choices were made.  
While we sought to include as many biopsy specimens as possible, in practice most of 
the biopsied patients were treated at one center (GOSH) and displayed a full range of disease 
severity scores at diagnosis. Since a typical overall range of disease severities is represented, 
our predictive model does accommodate a range of mild and severe patients. Importantly, a 
full range of severities of muscle pathologies are represented in the cohort analyzed for 
biopsy features. However, given that in the UK cohort as a whole those cases who had a 
muscle biopsy had more severe disease on average than those who did not have a biopsy, we 
acknowledge that this skew towards greater severity may limit the generalizability of our 
findings, until more centers generate further samples that represent the typical distribution of 
disease severity and also have known autoantibody status and longitudinal outcomes data on 
those cases. Nonetheless, our findings are internally valid with respect to the patients from 
whom biopsy, MSA status and longitudinal outcomes data are available at present.  
In summary, we have shown that muscle pathology and autoantibody status are 
correlated and that muscle pathology, influenced by MSA status, predicts the probability of 
remaining on treatment in JDM. Understanding the link between these early biomarkers of 
disease and long-term outcomes may give further insight into different sub-phenotypes of 
disease and lead to more tailored therapies. Our biomarker-based modelling may well be 
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applied to adult forms of inflammatory myositis and may also be a useful approach to the 
analysis of other rare diseases. 
 
ACKNOWLEDGEMENTS 
Funding for the UK JDM Cohort and Biomarker study has been provided by generous grants 
from the Wellcome Trust UK [085860], Action Medical Research UK [SP4252], The 
Myositis Support Group UK, Arthritis Research UK [14518, 20164], The Henry Smith 
Charity and Great Ormond Street Children's Charity [V1268], and the National Institute for 
Health Research (NIHR) Translational Research Collaboration (TRC) Rare Diseases. This 
research was supported by the NIHR Biomedical Research Centre at Great Ormond Street 
Hospital for Children NHS Foundation Trust and Institute of Child Health University College 
London (UCL). The JDM Cohort study is adopted onto the NIHR Comprehensive Research 
Network. KN is in receipt of a Wellcome Trust Intermediate Clinical Fellowship [097259]. 
This research has also been supported by The Bath Institute for Rheumatic Diseases and the 
MRC Confidence in Concepts Scheme (University of Bath). The Arthritis Research UK 
Centre for Adolescent Rheumatology at UCL, UCL Hospital and GOSH is supported by 
grants from Arthritis Research UK [20164] and Great Ormond Street Children's Charity. This 
is a summary of independent research funded by the NIHR’s Rare Diseases Translational 
Research Collaboration. The views expressed are those of the authors and not necessarily 
those of the NHS, the NIHR or the Department of Health. 
The authors thank Dr Maria de Iorio, Department of Statistical Science, UCL and 
Professor Jugnoo Rahi, Population, Policy and Practice Programme, UCL Institute of Child 
Health, for statistical guidance.  
Page 19 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
19 
 
The Juvenile Dermatomyositis Research Group would like to thank all of the patients 
and their families who contributed to the UK Juvenile Dermatomyositis Cohort and 
Biomarker Study. We thank all local research coordinators and principal investigators who 
have made this research possible. The members who contributed were as follows: 
Dr Kate Armon, Mr Joe Ellis-Gage, Ms Holly Roper, Ms Vanja Briggs and Ms Joanna Watts 
(Norfolk and Norwich University Hospitals), Dr Liza McCann, Mr Ian Roberts, Dr Eileen 
Baildam, Ms Louise Hanna, Ms Olivia Lloyd and Susan Wadeson (The Royal Liverpool 
Children’s Hospital, Alder Hey, Liverpool), Dr Phil Riley and Ms Ann McGovern (Royal 
Manchester Children’s Hospital, Manchester), Dr Clive Ryder, Mrs. Janis Scott, Mrs. 
Beverley Thomas, Professor Taunton Southwood, Dr Eslam Al-Abadi (Birmingham 
Children’s Hospital, Birmingham), Dr Sue Wyatt, Mrs Gillian Jackson, Dr Tania Amin, Dr 
Mark Wood, Dr Vanessa VanRooyen and Ms Deborah Burton (Leeds General Infirmary, 
Leeds), Dr Joyce Davidson, Dr Janet Gardner-Medwin, Dr Neil Martin, Ms Sue Ferguson, 
Ms Liz Waxman and Mr Michael Browne (The Royal Hospital for Sick Children, Yorkhill, 
Glasgow), Dr Mark Friswell, Professor Helen Foster, Mrs Alison Swift, Dr Sharmila Jandial, 
Ms Vicky Stevenson, Ms Debbie Wade, Dr Ethan Sen, Dr Eve Smith, Ms Lisa Qiao, Mr 
Stuart Watson and Ms Claire Duong (Great North Children’s Hospital, Newcastle), Dr Helen 
Venning, Dr Rangaraj Satyapal, Mrs Elizabeth Stretton, Ms Mary Jordan, Dr Ellen Mosley, 
Ms Anna Frost, Ms Lindsay Crate, Dr Kishore Warrier and Stefanie Stafford (Queens 
Medical Centre, Nottingham), Professor Lucy Wedderburn, Dr Clarissa Pilkington, Dr 
Nathan Hasson, Mrs Sue Maillard, Ms Elizabeth Halkon, Ms Virginia Brown, Ms Audrey 
Juggins, Dr Sally Smith, Mrs Sian Lunt, Ms Elli Enayat, Mrs Hemlata Varsani, Miss Laura 
Kassoumeri, Miss Laura Beard, Miss Katie Arnold, Mrs Yvonne Glackin, Ms Stephanie 
Simou, Dr Beverley Almeida, Dr Kiran Nistala, Dr Raquel Marques, Dr Shireena Yasin, Dr 
Claire Deakin, Ms Stefanie Dowle, Ms Charis Papadopoulou (Great Ormond Street Hospital, 
Page 20 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
20 
 
London), Dr Kevin Murray (Princess Margaret Hospital, Perth, Western Australia) Dr John 
Ioannou and Ms Linda Suffield (University College London Hospital, London) Dr Muthana 
Al-Obaidi, Ms Helen Lee, Ms Sam Leach, Ms Helen Smith, Dr Anne-Marie McMahon, Ms 
Heather Chisem and Ruth Kingshott (Sheffield’s Children’s Hospital, Sheffield); Dr Nick 
Wilkinson, Ms Emma Inness, Ms Eunice Kendall, Mr David Mayers, Ruth Etherton and Dr 
Kathryn Bailey (Oxford University Hospitals, Oxford); Dr Jacqui Clinch, Ms Natalie 
Fineman and Ms Helen Pluess-Hall (Bristol Royal Hospital for Children, Bristol); Ms 
Lindsay Vallance (Royal Aberdeen Children’s Hospital); Ms Louise Akeroyd (Bradford 
Teaching Hospitals); Dr Alice Leahy, Amy Collier, Rebecca Cutts, Dr Hans De Graaf, Dr 
Brian Davidson, Sarah Hartfree, Danny Pratt (University Hospital Southampton).  
 The authors declare that they have no competing interests.  
 
  
Page 21 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
21 
 
REFERENCES 
1. Rider LG, Katz JD, Jones OY. Developments in the classification and treatment of the 
juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2013;39:877–904.  
2. Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile 
dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology 
International Trials Organization criteria for inactive disease and the myositis disease activity 
assessment tool. Rheumatology (Oxford) 2014;53:1578–85. 
3. Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al. A national 
registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory 
myopathies: 10 years’ experience; the Juvenile Dermatomyositis National (UK and Ireland) 
Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopat. Rheumatology 
(Oxford) 2011;50:137–45.  
4. Lega J-C, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical 
phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis 
revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014;13:883–91.  
5. Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. 
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: 
a prospective cohort study. Arthritis Res Ther 2014;16:R138.  
6. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis 
autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 
(Baltimore) 2013;92:223–43.  
7. Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al. Clinical and 
laboratory features of fatal rapidly progressive interstitial lung disease associated with 
Page 22 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
22 
 
juvenile dermatomyositis. Rheumatology (Oxford) 2015;54:784–91.  
8. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-
TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. 
Rheumatology (Oxford) 2010;49:1726–33.  
9. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. 
Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile 
dermatomyositis. Rheumatology (Oxford) 2008;47:324–8.  
10. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WER, et al. 
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with 
calcinosis. Arthritis Rheum 2009;60:1807–14.  
11. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et 
al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody 
status and age at disease onset. Rheumatology (Oxford) 2014;53:2204–8.  
12. Wedderburn LR, Varsani H, Li CKC, Newton KR, Amato AA, Banwell B, et al. 
International consensus on a proposed score system for muscle biopsy evaluation in patients 
with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 
2007;57:1192–201.  
13. Varsani H, Charman SC, Li CK, Marie SKN, Amato AA, Banwell B, et al. Validation of 
a score tool for measurement of histological severity in juvenile dermatomyositis and 
association with clinical severity of disease. Ann Rheum Dis 2015;74:204–10.  
14. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 
1975;292:344–7.  
Page 23 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
23 
 
15. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. 
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile 
idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010;62:465–72.  
16. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. 
Validation and clinical significance of the Childhood Myositis Assessment Scale for 
assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis 
Rheum 2004;50:1595–603.  
17. Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for 
the initial treatment of moderately severe Juvenile dermatomyositis: Results of a children’s 
Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res 
(Hoboken) 2010;62:NA–NA.  
18. Team RDC. R : A Language and Environment for Statistical Computing. Team RDC, ed. 
Vienna Austria R Found Stat Comput 2015:ISBN 3–900051–07–0. Available at: 
http://www.r-project.org. 
19. Dinno A. dunn.test: Dunn’s test of multiple comparisons using rank sums. 2015. 
Available at: http://cran.r-project.org/package=dunn.test. 
20. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating 
equation approach. Biometrics 1988;44:1049–60.  
21. Twisk JWR, Smidt N, Vente W de. Applied analysis of recurrent events: a practical 
overview. J Epidemiol Community Health 2005;59:706–10.  
22. Twisk JWR. Applied Longitudinal Analysis for Epidemiology: A Practical Guide. 
Second. Cambridge, UK: Cambridge University Press; 2003. 
Page 24 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
24 
 
23. Hojsgaard S, Halekoh U, Yan J. The R Package geepack for Generalized Estimating 
Equations. J Stat Softw 2006;15:1–11. 
24. Barton K. MuMIn: Multi-model inference. 2015. Available at: http://cran.r-
project.org/package=MuMIn. 
25. Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. 
The prevalence of individual histopathologic features varies according to autoantibody status 
in muscle biopsies from patients with dermatomyositis. J Rheumatol 2015;42:1448–54.  
26. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. 
Tailoring therapies - improving the management of early breast cancer: St 
GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. 
Ann Oncol 2015;26:1533–46.  
27. Weening JJ, D’Agati VD, Schwartz MM, Seshan S V, Alpers CE, Appel GB, et al. The 
classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 
2004;65:521–30.  
28. Ruperto N, Pistorio A, Ravelli A, Hasija R, Guseinova D, Filocamo G, et al. Criteria to 
define response to therapy in paediatric rheumatic diseases. Eur J Clin Pharmacol 2011;67 
Suppl 1:125–31.  
 
  
Page 25 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
Prediction of outcomes in juvenile myositis 
 
25 
 
Figure 1. Distributions of total biopsy scores and histopathologist’s global pathology 
scores. (A) Correlation of total biopsy score and hVAS, including Spearman R correlation 
with 95% confidence interval (n=101). Distribution of (B) hVAS and (C) total biopsy score 
across MSA groups (n=69). Factorial ANOVA using the Kruskal-Wallis test was performed 
to analyze the distribution of these scores. There was a significant main effect of MSA on 
hVAS (χ
2
 (4, n=69) = 20.0, p=0.0005), with significant differences in hVAS between the 
anti-MDA5 and anti-Mi2 (p=0.0001), anti-MDA5 and anti-NXP-2 (p=0.007), anti-MDA5 
and anti-TIF1γ (p=0.04), and anti-MDA5 and no-detectable autoantibody (p=0.03) groups. 
There was also a significant main effect of MSA on total biopsy score (χ
2
 (4, n=69) = 20.4, 
p=0.0004), with significant differences in total biopsy score between the anti-MDA5 and 
anti-Mi2 (p=0.0009), anti-MDA5 and anti-NXP-2 (p=0.0006), anti-MDA5 and anti-TIF1γ 
(p=0.01), and anti-MDA5 and no-detectable autoantibody (p=0.04) groups. ANOVA, 
analysis of variance; hVAS, histopathologist’s visual analogue scale global pathology score; 
MSA, myositis-specific autoantibody.  
Figure 2. Longitudinal GEE modelling of treatment status over time according to 
myositis-specific autoantibody sub-groups and global muscle pathology score or total 
biopsy score. Forest plots depicting odds ratios with 95% confidence intervals for being on 
treatment estimated by GEE models fitted with MSA groups and either (A) hVAS or (B) total 
biopsy score as predictors. The no-detectable autoantibody group was used as the reference 
category. GEE, generalized estimating equations; hVAS, histopathologist’s visual analogue 
scale global pathology score; MSA, myositis-specific autoantibody.  
Figure 3. Longitudinal GEE models of the association between biopsy score and 
treatment status over time for selected MSA groups. Forest plots depicting odds ratios 
with 95% confidence intervals estimated by GEE models fitted with either (A) hVAS or (B) 
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total biopsy score as predictors. The no-detectable autoantibody, anti-NXP-2 and anti-TIF1γ 
MSA groups were included in these analyses. Predicted probability of being off treatment at 
5 years post-diagnosis as a function of either (C) hVAS or (D) total biopsy score for no-
detectable autoantibody, anti-NXP-2 and anti-TIF1γ MSA groups, derived from the GEE 
models. Dotted lines represent 95% confidence intervals. The median values for time from 
onset to diagnosis (0.214 years) and for time from diagnosis to biopsy (0.0602 years) were 
used in the calculations of predicted probabilities. GEE, generalized estimating equations; 
hVAS, histopathologist’s visual analogue scale global pathology score; MSA, myositis-
specific autoantibody.  
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Table 1. Demographic, clinical and serological features of the biopsy cohort (n=101) 
Feature Summary statistic 
Sex, n (%)  
Male 33 (32.7%) 
Female 68 (67.3%) 
Ethnicity, n (%)  
White 72 (71.3%) 
Black 12 (11.9%) 
South Asian 8 (7.9%) 
Other 9 (8.9%) 
Clinical features at biopsy, median [interquartile range]
a  
Age at onset (years) 6.1 [3.9-9.3] 
Physician’s global assessment (PGA) 4.1 [2.0-7.0] 
MMT8 55.0 [40.0-71.5] 
CMAS 29 [18.75-45] 
Creatine kinase (units/L) 213 [55-1019] 
Clinical features at biopsy, median [interquartile range]  
Time from disease onset to diagnosis, (months) 2.6 [1.5-7.5] 
Time from diagnosis to biopsy, (months) 0.72 [0.39-0.92] 
Biopsy performed > 1 month after diagnosis, n (%) 17 (16.8%) 
On steroids at biopsy, n (%)
b 
12 (12.2%)  
Myositis-specific autoantibodies, n (%)
c 
53 (58.9%) 
Anti-TIF1γ 18 (20.0%) 
Anti-NXP-2 15 (16.7%) 
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Anti-MDA5 11 (12.2%) 
Anti-Mi2 5 (5.6%) 
Anti-SRP 2 (2.2%) 
Anti-PL7 1 (1.1%) 
Anti-SAE 1 (1.1%) 
Myositis-associated autoantibodies, n (%) 9 (10.0%) 
Anti-PM-Scl 6 (6.7%) 
Anti-U1RNP 2 (2.2%) 
Anti-Topo 1 (1.1%) 
Unidentified autoantibodies, n (%) 8 (8.9%) 
No-detectable autoantibodies, n (%) 20 (22.2%) 
aClinical features were missing for some patients: n=11 (PGA), n=42 (MMT8), n=17 (CMAS), n=30 
(creatine kinase).  
b
Steroids not recorded at the biopsy time-point for 3 individuals (3.0%). 
cAutoantibodies were screened for in 90 biopsied patients. Percentages reflect the number of patients 
with a given antibody as a proportion of total tested patients.  
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Table 2. Summary of alternative GEE models 
Predictor Variable Odds Ratio 95% Confidence 
Interval 
P-value 
Univariate models for hVAS, total biopsy score and MSA (n=69) 
hVAS 1.10 0.92 – 1.31 0.28 
Total biopsy score 1.03 0.96 – 1.10 0.43 
MSA    
          No-detectable (n=20) 1.00 - - 
          Anti-MDA5 (n=11) 1.69 0.38 – 7.60 0.50 
          Anti-NXP-2 (n=16) 1.61 0.41 – 6.36 0.50 
          Anti-TIF1γ (n=17) 2.06 0.46 – 9.28 0.35 
          Anti-Mi2 (n=5) 0.68 0.24 – 1.90 0.46 
Bivariate model with PGA and MSA (n=44)a 
PGA 1.27 0.92 – 1.76 0.15 
MSA    
          No-detectable (n=10) 1.00  -   -  
          Anti-MDA5 (n=9) 1.56 0.22 – 11.00 0.65 
          Anti-NXP-2 (n=9) 0.44 0.08 – 2.55 0.36 
          Anti-TIF1γ (n=12) 1.51 0.20 – 11.16 0.69 
          Anti-Mi2 (n=4) 0.78 0.09 – 7.00 0.83 
GEE, generalized estimating equations; hVAS, histopathologist’s visual analogue scale 
global pathology score; MSA, myositis-specific autoantibody; PGA, physician’s global 
assessment. 
aPGA at diagnosis was available for n=44 patients.  
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Table 3. Summary of model comparisons 
 QIC
a 
Model 
selection 
weight
b 
ANOVA
c
 
χ
2 
ANOVA 
p-value 
Comparison of bivariate models (hVAS and MSA or Total biopsy score and MSA) to 
nested univariate and null models, for models fitted with all MSA patients (n=69) 
Bivariate (hVAS and MSA) 315 - - - 
          Univariate (hVAS only) 349 1 10.2 (4) * 0.038 
          Univariate (MSA only) 355 1 7.6 (1) ** 0.0058 
          Null (Time only) 350 1 10.5 (5) 0.063 
Bivariate (Total biopsy score and MSA) 336 - - - 
          Univariate (Total biopsy score only) 351 0.999 8.6 (4) 0.073 
          Univariate (MSA only) 355 1 4.3 (1) * 0.038 
          Null (Time only) 350 0.999 8.6 (5) 0.13 
Comparison of bivariate model fitted with MSA and PGA to bivariate models fitted with 
MSA and either hVAS or total biopsy score (n=44)
d
 
PGA and MSA            316    
          hVAS and MSA 263 0  -   -  
          Total biopsy score and MSA 293 0  -   -  
Comparison of univariate models to bivariate and null models, for models fitted with 
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anti-NXP-2, anti-TIF1γ and no-detectable MSA patients (n=52) 
Univariate (hVAS) 203 - - - 
          Bivariate (hVAS and MSA) 199 0.85 2.0 (2) 0.36 
          Null (Time) 247 1 8.3 (1) ** 0.004 
Univariate (Total biopsy score) 228 - - - 
          Bivariate (Total biopsy score and 
MSA) 
235 0.96 0.7 (2) 0.71 
          Null (Time) 247 1 6.2 (1) * 0.013 
ANOVA, analysis of variance; hVAS, histopathologist’s visual analogue scale global 
pathology score; MSA, myositis-specific autoantibody; PGA, physician’s global assessment 
at diagnosis; QIC, quasi-Akaike information criterion. 
a
The quasi-Akaike information criterion is a measurement of the relative quality of the GEE 
models. Models with lower values indicate a better fit.   
b
Model selection weight representing the proportion of weight to be given to the bivariate 
models as compared to their respective nested univariate model (rows 2-4, 6-8, 10-11, 13-14), 
or the model with PGA and MSA as compared to the models with biopsy score and MSA 
(rows 16-17), on a scale of 0-1, when the bivariate, univariate and null models are compared 
as indicated. Values of or close to 1 indicate the preferred model. 
c
ANOVA comparison of bivariate model to nested or null models, with degrees of freedom 
given in parentheses. The ANOVA tests for a reduction in residual sum of squares, with p-
values below 0.05 indicating a significantly improved fit for the data.  
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d
PGA at biopsy was available for n=44 patients. For the purpose of these model comparisons, 
GEE models with MSA and hVAS or MSA and total biopsy score were fitted on the 
equivalent dataset.  
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Figure 1. Distributions of total biopsy scores and histopathologist’s global pathology scores. (A) Correlation 
of total biopsy score and hVAS, including Spearman R correlation with 95% confidence interval (n=101). 
Distribution of (B) hVAS and (C) total biopsy score across MSA groups (n=69). Factorial ANOVA using the 
Kruskal-Wallis test was performed to analyze the distribution of these scores. There was a significant main 
effect of MSA on hVAS (χ2 (4, n=69) = 20.0, p=0.0005), with significant differences in hVAS between the 
anti-MDA5 and anti-Mi2 (p=0.0001), anti-MDA5 and anti-NXP-2 (p=0.007), anti-MDA5 and anti-TIF1γ 
(p=0.04), and anti-MDA5 and no-detectable autoantibody (p=0.03) groups. There was also a significant 
main effect of MSA on total biopsy score (χ2 (4, n=69) = 20.4, p=0.0004), with significant differences in 
total biopsy score between the anti-MDA5 and anti-Mi2 (p=0.0009), anti-MDA5 and anti-NXP-2 (p=0.0006), 
anti-MDA5 and anti-TIF1γ (p=0.01), and anti-MDA5 and no-detectable autoantibody (p=0.04) groups. 
ANOVA, analysis of variance; hVAS, histopathologist’s visual analogue scale global pathology score; MSA, 
myositis-specific autoantibody.  
82x160mm (300 x 300 DPI)  
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Figure 2. Longitudinal GEE modelling of treatment status over time according to myositis-specific 
autoantibody sub-groups and global muscle pathology score or total biopsy score. Forest plots depicting 
odds ratios with 95% confidence intervals for being on treatment estimated by GEE models fitted with MSA 
groups and either (A) hVAS or (B) total biopsy score as predictors. The no-detectable autoantibody group 
was used as the reference category. GEE, generalized estimating equations; hVAS, histopathologist’s visual 
analogue scale global pathology score; MSA, myositis-specific autoantibody.  
82x150mm (300 x 300 DPI)  
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Figure 3. Longitudinal GEE models of the association between biopsy score and treatment status over time 
for selected MSA groups. Forest plots depicting odds ratios with 95% confidence intervals estimated by GEE 
models fitted with either (A) hVAS or (B) total biopsy score as predictors. The no-detectable autoantibody, 
anti-NXP-2 and anti-TIF1γ MSA groups were included in these analyses. Predicted probability of being off 
treatment at 5 years post-diagnosis as a function of either (C) hVAS or (D) total biopsy score for no-
detectable autoantibody, anti-NXP-2 and anti-TIF1γ MSA groups, derived from the GEE models. Dotted lines 
represent 95% confidence intervals. The median values for time from onset to diagnosis (0.214 years) and 
for time from diagnosis to biopsy (0.0602 years) were used in the calculations of predicted probabilities. 
GEE, generalized estimating equations; hVAS, histopathologist’s visual analogue scale global pathology 
score; MSA, myositis-specific autoantibody.  
107x66mm (300 x 300 DPI)  
 
 
Page 37 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
